Soticlestat Completed Phase 2 Trials for Dup15Q Syndrome / CDKL5 Deficiency Disease Treatment

Indications	Status	Purpose	Phase
DBCOND0146821 (Dup15Q Syndrome) DBCOND0114503 (CDKL5 Deficiency Disease)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT03694275	A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)	Soticlestat (DB16987)